New ALS therapy extends survival and reverses some neuromuscular damage in animals innovationtoronto.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from innovationtoronto.com Daily Mail and Mail on Sunday newspapers.
A new drug has been approved by the Food and Drug Administration (FDA) for a rare, inherited form of amyotrophic lateral sclerosis (ALS). Called tofersen, the drug developed by Biogen Inc. and based in part on research conducted at Washington University School of Medicine in St. Louis slows the progression of the deadly, paralyzing disease.
An international phase 3 clinical trial for a drug developed to treat a rare, inherited form of amyotrophic lateral sclerosis (ALS) showed that it reduced molecular signs of the fatal disease, but at six months did not improve motor control and muscle strength, according to Washington University School of Medicine researchers.